Browse the evidence

Peripheral administration of the GLP-1 receptor agonist liraglutide induces weight loss primarily by crossing the blood-brain barrier to activate GLP-1 receptors on POMC/CART neurons in the arcuate nucleus (ARC), rather than via vagal or area postrema pathways.

Liraglutide reduces body weight by entering the brain and activating specific neurons (POMC/CART) in the arcuate nucleus that regulate appetite. This central action is the primary driver of weight loss, distinct from peripheral effects like slowed stomach emptying. The drug requires crossing the blood-brain barrier to bind to GLP-1 receptors on these specific neurons.

Insulin resistance is a primary driver of cardiovascular risk in obesity, whereas obesity itself (without insulin resistance) does not significantly increase mortality or cardiovascular risk.

Having excess body fat does not automatically mean you have a high risk of heart disease or early death. The critical factor is insulin resistance. If you are obese but metabolically healthy (normal insulin sensitivity), your cardiovascular risk may not be significantly elevated. Focus on improving metabolic health through activity and diet rather than just weight loss.

The 'no-dipper' blood pressure pattern (lack of nocturnal BP reduction) is independently associated with higher cardiovascular risk and organ damage, regardless of standard Framingham risk scores or confirmed hypertension diagnosis.

If you have high blood pressure or cardiovascular risk, standard office checks might not tell the whole story. Ask your doctor about 24-hour ambulatory blood pressure monitoring (ABPM). This test checks if your blood pressure drops at night (dipping). If it doesn't (no-dipper), your risk of heart attack, stroke, and kidney damage is higher, even if your daytime readings look okay. Managing this pattern may require specific timing of medications (chronotherapy) or lifestyle changes to restore normal nighttime drops.

SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin) improve glycemic control in type 2 diabetes by blocking glucose reabsorption in the renal proximal tubule, inducing glycosuria.

If you have Type 2 Diabetes and your kidneys are functioning adequately (eGFR > 30), SGLT2 inhibitors like empagliflozin or dapagliflozin can help lower your blood sugar by causing your kidneys to excrete glucose in your urine. This is done via a daily oral pill. While there is a risk of genital infections, they are generally mild and manageable. The key benefit is that these drugs also offer cardiovascular and renal protection beyond just lowering blood sugar.

Once-weekly subcutaneous dulaglutide (1.5 mg) is administered to patients with type 2 diabetes to evaluate its effect on cardiovascular outcomes, including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.

This paper outlines the design of the REWIND trial, which tests whether once-weekly dulaglutide (1.5 mg) reduces cardiovascular events (heart attack, stroke, cardiovascular death) in people with type 2 diabetes who are at high risk. The trial includes nearly 10,000 participants with a mean age of 66, many of whom have prior cardiovascular disease or risk factors. The results of this trial will help determine if dulaglutide is an effective cardiovascular protective agent for this population.

Intramuscular androgen receptor content, rather than systemic or intramuscular hormone levels, determines the magnitude of resistance training-induced skeletal muscle hypertrophy in healthy, young men.

If you are a healthy, young man who already lifts weights regularly, your muscle growth potential is likely determined by your genetic muscle receptor density, not your blood testosterone levels. You cannot change your receptor density with supplements or TRT if your levels are already normal. Focus on consistent, progressive resistance training rather than trying to manipulate hormones.

Obesity pathophysiology is driven by complex interactions between genetic susceptibility, environmental factors, and hormonal signaling (leptin, insulin, ghrelin, GLP-1) that regulate energy balance, rather than simple caloric imbalance alone.

Obesity is not just a failure of willpower; it involves complex hormonal signals (like leptin and insulin) and genetics. Effective management often requires addressing these biological drivers, potentially through lifestyle changes combined with medical therapies that target these specific pathways.

High body mass index (BMI) is a strong independent risk factor for the development and progression of Chronic Kidney Disease (CKD), primarily driven by compensatory glomerular hyperfiltration and increased intraglomerular pressure.

Maintaining a healthy weight is one of the most effective ways to protect your kidneys. Excess body weight forces your kidneys to work harder (hyperfiltration), which can cause long-term damage. While weight loss is complex in advanced kidney disease, preventing obesity is a primary strategy for avoiding kidney failure.

Semaglutide 2.4 mg once weekly does not increase the risk of developing symptoms of depression or suicidal ideation/behavior compared to placebo in people with overweight or obesity without known major psychopathology.

If you are considering semaglutide for weight loss and are worried about your mental health, know that large clinical trials show it does not increase the risk of depression or suicidal thoughts compared to a placebo. While you should still monitor your mood as recommended, the medication itself is not causing these psychiatric issues. This is particularly reassuring if you have no history of major mental health conditions.

Obesity directly causes chronic kidney disease (CKD) and end-stage renal disease (ESRD) through compensatory hyperfiltration, glomerular hypertension, and adipose-derived inflammatory mediators, independent of diabetes and hypertension.

Maintaining a healthy body weight is critical for kidney health. Obesity increases pressure inside the kidney's filtering units (glomeruli) and releases hormones that cause inflammation and scarring, leading to chronic kidney disease. This risk exists even if you do not have diabetes or high blood pressure. Preventing obesity through lifestyle changes is the most effective way to protect your kidneys.

Exercise combined with calorie restriction does not induce browning (brite cell formation) in human subcutaneous white adipose tissue; instead, it is associated with decreased UCP1 expression, suggesting a 'whitening' or adaptive response to energy deficit rather than increased thermogenesis.

If you are losing weight through exercise and diet, do not expect your fat cells to turn into 'brown fat' that burns extra calories. Your body actually adapts by reducing the expression of thermogenic proteins (like UCP1) in your white fat, likely to conserve energy during a deficit. This is a normal, adaptive response to weight loss, not a failure of your exercise program. The weight loss is driven by the calorie deficit, not by creating new heat-generating fat cells.

GLP-1 RAs can cause clinically significant drug-drug interactions (DDIs) by delaying gastric emptying, particularly affecting the absorption of oral contraceptives and levothyroxine.

If you take oral contraceptives or levothyroxine, be aware that GLP-1 drugs can change how well these work by slowing stomach emptying. Your doctor may need to monitor your levels or adjust doses. Use backup contraception if advised.

Integrase strand transfer inhibitors (INSTIs), particularly dolutegravir and bictegravir, are the primary drivers of weight gain in modern ART regimens, with effects observed as early as 4 weeks post-initiation.

If you are taking an INSTI (like dolutegravir or bictegravir), be aware that these drugs are strongly linked to weight gain, often starting within weeks of taking them. This is a known side effect of the drug class, not just your lifestyle. If you are at high risk (e.g., woman, Black patient), discuss your concerns with your doctor. They might consider alternative regimens, though these may have other trade-offs.

GLP-1 receptor activation suppresses glucagon secretion primarily through an indirect mechanism involving somatostatin release from delta-cells, rather than direct action on alpha-cells.

GLP-1 drugs help control blood sugar not just by boosting insulin, but by suppressing glucagon (a hormone that raises blood sugar). This suppression happens indirectly by stimulating other cells (delta-cells) to release somatostatin, which then inhibits glucagon. This dual action makes GLP-1 drugs effective for lowering blood glucose.

Ghrelin, the 'hunger hormone', directly stimulates reward pathways in the brain (VTA and NAc) to increase motivation and willingness to work for food, particularly palatable/high-fat foods.

Hunger isn't just an empty stomach; it's a biological signal that boosts your brain's reward system for food. This is why cravings feel so compelling. Understanding this biological drive can help separate the feeling of hunger from the act of eating.

GLP-1 receptor agonists directly modulate immune cell function, specifically suppressing T-cell activity and pro-inflammatory cytokine release, independent of metabolic changes.

GLP-1 medicines interact directly with your immune system. They can dampen the activity of T cells, which are key drivers of inflammation. This direct interaction helps reduce the production of inflammatory markers like TNF-α and IL-2, contributing to overall health benefits beyond blood sugar control.

GLP-1 receptor agonists reduce cardiovascular events and atherosclerosis progression through weight-loss-independent anti-inflammatory mechanisms involving endothelial and immune cell modulation.

GLP-1 medications like semaglutide and liraglutide are proven to reduce the risk of heart attacks, strokes, and cardiovascular death in people with type 2 diabetes and obesity. This protection is partly due to direct anti-inflammatory effects on blood vessels, independent of weight loss. These benefits are significant enough to be a primary reason for prescribing these drugs in high-risk patients.

Higher habitual dairy intake does NOT causally affect glycemic traits (fasting glucose, insulin, HbA1c) in adults, despite observational associations.

You do not need to avoid dairy for blood sugar control. The study suggests dairy does not causally affect glycemic traits, so it can be included in a healthy diet without fear of worsening blood sugar levels.

SPARC acts as a priming signal for the NLRP3 inflammasome in macrophages, driving chronic inflammation associated with obesity.

Chronic inflammation in obesity is driven by SPARC activating immune cells. Reducing SPARC levels, as seen with weight loss, reduces this inflammation.

GLP1R agonism reduces coronary artery disease (CAD) risk primarily through body weight lowering (BMI) rather than through the reduction of type 2 diabetes (T2D) liability.

If you are using a GLP-1 agonist (like semaglutide or tirzepatide) for heart health, the primary benefit comes from the weight loss it induces, not just from lowering blood sugar. Even if your blood sugar is already well-controlled, the drug's effect on reducing body weight is what significantly lowers your risk of coronary artery disease. This supports using these medications for cardiovascular prevention in obese individuals, regardless of diabetic status.

Stimulating the release of endogenous intestinal GIP via K-cell activation reduces food intake and body weight in mice through a central nervous system mechanism.

This research suggests that the hormone GIP, released from the gut after eating, plays a direct role in signaling satiety to the brain. While this is currently demonstrated via genetic manipulation in mice, it implies that therapies enhancing natural GIP release or mimicking its action could help reduce food intake and body weight, potentially offering an alternative or complement to GLP-1 based treatments.

Co-ingesting protein with alcohol following strenuous exercise attenuates alcohol-induced intramyocellular apoptosis and prevents the inhibition of autophagy, whereas alcohol with carbohydrate triggers apoptosis.

If you consume alcohol after a strenuous workout, mix it with protein rather than just carbohydrates or water. This study shows that protein helps protect muscle cells from apoptosis (cell death) and supports mitochondrial health, whereas alcohol with carbohydrates triggered significant DNA fragmentation and cell stress. This does not mean alcohol is 'good' for recovery, but protein co-ingestion appears to mitigate some of the cellular damage compared to other common mixing strategies.

In Type 1 Diabetes, fracture incidence rates have remained stable or increased in women, despite overall improvements in diabetes management and the adoption of newer technologies.

If you have Type 1 Diabetes, especially if you are a woman, be aware that your fracture risk may not be decreasing as much as it is for Type 2 Diabetes patients. Focus on preventing hypoglycemia, as low blood sugar events are linked to higher fracture risk. Discuss bone health specifically with your endocrinologist.

PPAR agonists (specifically pioglitazone) improve individual histological features of NASH (steatosis, ballooning, inflammation) and can improve fibrosis.

Pioglitazone, a PPAR agonist, improves liver inflammation and fat in NASH patients. It is taken orally (30-45 mg daily). A significant side effect is weight gain (~2.5 kg), which might be undesirable for obese patients. It can also improve fibrosis.